Voyager Therapeutics (VYGR) Projected to Post Earnings on Tuesday

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) will likely be announcing its Q1 2025 earnings results before the market opens on Tuesday, May 6th. Analysts expect Voyager Therapeutics to post earnings of ($0.35) per share and revenue of $13.55 million for the quarter.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.18). The company had revenue of $6.47 million during the quarter, compared to the consensus estimate of $13.55 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. On average, analysts expect Voyager Therapeutics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Voyager Therapeutics Stock Down 5.5 %

VYGR traded down $0.19 during trading on Friday, reaching $3.24. The stock had a trading volume of 756,113 shares, compared to its average volume of 445,631. Voyager Therapeutics has a 1-year low of $2.75 and a 1-year high of $9.55. The firm has a market capitalization of $179.21 million, a price-to-earnings ratio of 4.56 and a beta of 0.95. The stock has a 50 day moving average of $3.52 and a two-hundred day moving average of $4.93.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Canaccord Genuity Group lowered their target price on Voyager Therapeutics from $14.00 to $12.00 and set a "buy" rating on the stock in a report on Thursday, March 13th. Wedbush reissued an "outperform" rating on shares of Voyager Therapeutics in a research note on Wednesday, March 12th. Wells Fargo & Company set a $10.00 price target on Voyager Therapeutics and gave the company an "overweight" rating in a report on Wednesday, March 12th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Voyager Therapeutics in a research report on Wednesday, March 12th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $30.00 target price on shares of Voyager Therapeutics in a research report on Tuesday, April 8th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $13.97.

Insider Activity at Voyager Therapeutics

In other Voyager Therapeutics news, CEO Alfred Sandrock sold 10,885 shares of Voyager Therapeutics stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $3.43, for a total transaction of $37,335.55. Following the transaction, the chief executive officer now owns 430,931 shares of the company's stock, valued at $1,478,093.33. The trade was a 2.46 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 6.39% of the stock is owned by insiders.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.